All News
Filter News
Found 808,606 articles
-
TherapeuticsMD Announces Oral Presentations on BIJUVA and ANNOVERA, and Poster Presentations Related to Menopause Symptoms and Treatments at 2019 ISSWSH/ISSM Joint Meeting
3/8/2019
TherapeuticsMD, Inc. announced the schedule of oral presentations on clinical data for BIJUVATM and ANNOVERATM, and poster presentations related to menopause symptoms and treatments, at the International Society for the Study of Women’s Sexual Health and the International Society of Sexual Medicine joint annual meeting in Atlanta, GA on March 8-9, 2019.
-
AngioDynamics Wins Patent Infringement Dispute With Bard
3/8/2019
AngioDynamics, Inc. announced that the United States District Court for the District of Delaware, on day four of a jury trial at the close of C.R. Bard’s case, granted judgement as a matter of law under rule 50 in favor of AngioDynamics, dismissing Bard’s suit alleging that certain of AngioDynamics’ implantable port products infringed three Bard patents.
-
China-Based High-Tech Firm P&P Biotech Obtains US Patent for Its Platform Technology
3/8/2019
China-based high-tech firm P&P Biotech has been awarded a patent from the US for its hydrophilic, electro-spinning composite scaffold biomaterial and related methods and applications that are used in tissue regeneration, signalizing that China has moved into a leadership position in terms of biotechnology development.
-
Palo Alto Health Sciences Obtains DMEPOS Accreditation BY HQAA
3/8/2019
Palo Alto Health Sciences, Inc. announced that it has received full accreditation from the Healthcare Quality Association on Accreditation as a durable medical equipment, prosthetics, orthotics and supplies provider.
-
American Renal Associates Holdings, Inc. Announces Delay in Release of Fourth Quarter and Year-End 2018 Earnings, Filing of 2018 10-K
3/8/2019
American Renal Associates Holdings, Inc. announced that it will delay the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and the issuance of its earnings release for the fourth quarter and full year 2018.
-
Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement
3/8/2019
Stellar Biotechnologies, Inc. has executed a share exchange agreement with privately-held Edesa Biotech Inc., a Canadian company, and Edesa's shareholders to create a company focused on the development of innovative therapeutics for dermatological and gastrointestinal indications with clear unmet medical needs.
-
Daxko Acquires GroupEx PRO to Bring Streamlined, Integrated Group Fitness Program Management to a Growing Number of Health and Wellness Centers
3/8/2019
Daxko announced that it acquired GroupEx PRO, a privately held best of breed, web-based group exercise management portal utilized by group fitness departments across the country.
-
Le Bonheur Children's Hospital Announces New President
3/8/2019
Le Bonheur Children's Hospital announced that Michael Wiggins, MBA, FACHE, will become its next president.
-
Xencor Announces Closing of Research Collaboration and License Agreement with Genentech
3/8/2019
Xencor, Inc. announced the closing of its research collaboration and license agreement with Genentech, a member of the Roche Group, following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976.
-
Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO)
3/8/2019
Tildacerfont demonstrates potential to become the first approved therapy for congenital adrenal hyperplasia, a rare endocrine disorder
-
Government of Canada Announces Funding for Innovative Project to Help Prevent Teen Dating Violence
3/8/2019
Project will integrate technology and art therapy tools to teach youth how to identify and prevent gender-based violence
-
Jackson Healthcare to Host March 8 Campus Expansion Grand Opening and Ribbon-Cutting Event
3/8/2019
Company to Unveil Eight-Story, State-of-the-Art Office Tower and Multi-Level Amenities Center on Corporate Campus
-
FDA takes steps to help reduce risks associated with surgical staplers and implantable staples
3/8/2019
The FDA issued a Letter to Health Care Providers to alert them that the agency is aware of an increasing number of medical device reports associated with the use of surgical staplers for internal use and implantable surgical staples—common devices used in many surgeries—and to provide updated recommendations to help reduce risks associated with their use.
-
MLP CARE Completed the Year With Growth Above Expectations in 2018
3/8/2019
MLP Sağlık Hizmetleri A.Ş., the leading private healthcare service provider in Turkey, announces its financial results for the full year ended December 31, 2018.
-
NephCure Kidney International Announces Three New Scientific Advisory Board Members
3/8/2019
NephCure Kidney International is proud to announce the addition of three new members to its Scientific Advisory Board.
-
Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast
3/8/2019
Agenus Inc., an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, March 14, 2019.
-
Health Canada Sets New Guideline for Lead in Drinking Water
3/8/2019
Latest in series of Government actions to protect Canadians from exposure to lead
-
Rhythmlink Announces Investment Partnership with New Heritage
3/8/2019
Rhythmlink International, LLC is pleased to announce an exciting new investment partnership with New Heritage Capital, a Boston-based private equity firm that specializes in growing founder-owned businesses.
-
Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
3/8/2019
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, issued an update on the Exchange of Rights for Common and Series B Preferred Shares announced February 22, 2019.
-
Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation
3/8/2019
Arena Pharmaceuticals, Inc. presented new Phase 2 data from its investigative drug candidates etrasimod and olorinab at the 14th Congress of European Crohn's and Colitis Organisation.